Preliminary Findings from DoD-Supported Electroceutical Dressing Study Presented at MHSRS 2025
Updated: 5 days ago
COLUMBUS, Ohio — August 7, 2025 — Investigators from the 112-patient randomized clinical study of Pavaka's six-volt Gen 1 electroceutical dressing presented preliminary findings today at the 2025 Military Health System Research Symposium (MHSRS). Clinical results are from Gen 1; Gen 2 has not been studied in patients.
MHSRS is the Military Health System's annual scientific meeting. It brings together military, academic and industry researchers working on problems that matter to service members, from point-of-injury care to long-term recovery.
The presentation was part of a breakout session titled "Old Antibiotics, New Strategies: Repurposing & Combining FDA-Approved Drugs to Combat Wound Infection." Gayle M. Gordillo, MD, a co-investigator on the study, presented on behalf of the team led by principal investigator Sashwati Roy, PhD.
The study (ClinicalTrials.gov NCT04794621) was supported by the U.S. Department of Defense and the Naval Medical Research Center. It enrolled 112 participants across three Indianapolis-area sites and was completed in 2023. Its primary outcome concerned wound biofilm, the protective communities of bacteria that can stall healing and resist conventional treatment.
The findings presented at MHSRS were preliminary. The investigators are preparing the full results for peer-reviewed publication, and Pavaka will share them once they are published.
For Pavaka, MHSRS is a natural audience. Infection in traumatic and chronic wounds is a serious concern in military medicine, especially in prolonged field care, where evacuation may be delayed and antibiotic options can be limited. The company's investigational dressing generates a low-level electric field at the wound surface and is being designed with those operational realities in mind.
Pavaka thanks the investigators, the study participants and the Department of Defense sponsors whose work made the presentation possible.
MHSRS 2025 marked the first time preliminary findings from the randomized study were shared with this audience.
Eleven days later, Rev1 Ventures named Pavaka to its Fall 2025 Customer to Capital accelerator cohort.
"Seeing this work shared with the military medicine community is exactly where it belongs. Service members are among the people who stand to benefit most if this technology proves out, and their clinicians deserve to see the science first." — Brent Toto, CEO and Co-Founder
Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.
About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.




Comments